LEADING THE SMALL MOLECULE FIGHT AGAINST RSV

Driving small molecule antiviral development for Respiratory Syncytial Virus infection
RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: RV521

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial
Meet the Team...

Dr Ken Powell

Chairman

Dr Eddy Littler

Chief Executive Officer

Dr Stuart Cockerill

Chief Scientific Officer, Founder

Dr Rachel Harland

Chief Operating Officer

Dr Neil Mathews

Project Director, Founder

Max Herrmann

Chief Financial Officer

Dr Elaine Thomas

Head of Virology

Dr Seth Hetherington

Chief Medical Officer
Latest News
Virologist Position (Durham Area)

ReViral are currently recruiting a Virologist to join our laboratory team based in the Durham area, UK, to support the company's antiviral drug discovery and development...

Read more...
Virologist Position (Stevenage)

ReViral are currently recruiting a Virologist to join our laboratory team based in Stevenage, UK.

This is a practical laboratory-based position and we are looking for...

Read more...
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

London, UK, 26th February 2019: ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial...

Read more...
Contact us...
Privacy Policy
© Reviral Ltd 2019